OncoMed Partnerships and Competitors Explored

OncoMed has partnered with several companies to advance its pipeline of cancer therapies. Celgene, a global biopharmaceutical company, acquired OncoMed in 2019 for $300 million, expanding its presence in the cancer treatment market.

OncoMed's partnerships with other companies have helped it navigate the complex and highly competitive field of cancer research. For example, its collaboration with GlaxoSmithKline (GSK) and Celgene has led to the development of several promising cancer therapies.

OncoMed's focus on cancer stem cell biology has set it apart from competitors. By targeting cancer stem cells, OncoMed aims to develop more effective treatments with fewer side effects.

The company's unique approach has attracted significant attention from other biotech companies, but it also faces stiff competition from established players like Pfizer and Merck.

Here's an interesting read: The Michaels Companies

OncoMed had at least two direct competitors in 2013: Stemline Therapeutics and Verastem. Both were public American companies.

By 2014, the number of firms pursuing therapies targeting cancer stem cells had grown significantly, but Stemline and Verastem remained the only two competitors solely focused on cancer stem cells.

OncoMed is considered the best positioned of the three companies focused on the cancer stem cell area, according to one analyst.

OncoMed had at least two direct competitors in 2013: Stemline Therapeutics and Verastem, both public American companies.

By 2014, the list of firms pursuing therapies targeting cancer stem cells had grown to include several major players.

Boston Biomedical, a subsidiary of Dainippon Sumitomo Pharma, was one of the new entrants in the field.

GlaxoSmithKline, Astellas Pharma, Sanofi, and Pfizer also began pursuing cancer stem cell therapies around the same time.

However, Stemline and Verastem remain the only two competitors solely focused on cancer stem cells.

One analyst believes OncoMed is the best positioned of the three companies focused on the cancer stem cell area.

Mereo BioPharma is a biopharmaceutical company that has partnered with a pharma company to develop and commercialize its lead product, bermekimab. This partnership will provide Mereo BioPharma with the necessary resources and expertise to advance bermekimab through late-stage clinical development and commercialization.

The partnership will enable Mereo BioPharma to focus on its core strengths while leveraging the pharma company's global reach and commercial capabilities. This will be a significant step forward for Mereo BioPharma, allowing it to bring its innovative treatment to patients worldwide.

Consider reading: Statera BioPharma

As of January 2017, OncoMed had seven clinical-stage drugs in development. This is a significant number, showing the company's dedication to finding new treatments for various diseases.

The clinical pipeline at OncoMed was quite extensive, with several drugs in different stages of development. Here's a breakdown of some of the drugs mentioned in the article:

OncoMed was also collaborating with other companies to develop some of these drugs. For example, they were working with Celgene on demcizumab, OMP-305B83, and OMP-131R10, and with GlaxoSmithKline on tarextumab and brontictuzumab.